Indian drugmaker joins race to find COVID-19 vaccine

Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

India approves COVID-19 vaccines ahead of huge rollout

5 January 2021 India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week.

Medtech

India calls for IP waiver to combat COVID-19

2 March 2021 The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.

Big Pharma

India regulator U-turns on controversial generics-only policy

31 August 2023 National Medical Commission has put new regulations on hold that would have made prescribing generics mandatory | Move comes after pressure from doctors’ organisation and pharma firms.

More on this story

Asia

India approves COVID-19 vaccines ahead of huge rollout

Medtech

India calls for IP waiver to combat COVID-19

2 March 2021 The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.

Big Pharma

India regulator U-turns on controversial generics-only policy

More on this story

Asia

India approves COVID-19 vaccines ahead of huge rollout

Medtech

India calls for IP waiver to combat COVID-19

2 March 2021 The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.

Big Pharma

India regulator U-turns on controversial generics-only policy